Vraylar 1.5 MG capsule 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FA3L4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,820
Award facts
- Contract value 100% obligated
- $11,819.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 23, 2026, the Defense Logistics Agency awarded a $11,819.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vraylar 1.5 mg capsules (30-count). This non-competitive delivery order represents performance through January 26, 2026, with fulfillment occurring at the awardee's Conshohocken, Pennsylvania facility. The award is executed under AmerisourceBergen's parent company, Cencora, Inc., which holds a substantial Indefinite Delivery Contract valued at $999,999,999.00 with DLA Troop Support Medical through December 2031, serving as the overarching vehicle for this and similar pharmaceutical supply orders to support military healthcare programs globally.
AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor for federal medical procurement, particularly for Department of Defense and military healthcare systems. The delivery order for Vraylar, a neurological treatment medication, exemplifies the company's role in supplying brand-name and generic medications across multiple therapeutic domains to support military treatment facilities and veterans' healthcare programs. As a major healthcare solutions provider registered in the System for Award Management, AmerisourceBergen continues to fulfill federal requirements through the DLA's comprehensive pharmaceutical supply chain, which encompasses vaccines, specialty medications, medical devices, and related healthcare commodities required across military installations and federal healthcare systems worldwide.
Quick answers
Who was awarded contract SPE2DR26FA3L4?
SPE2DR26FA3L4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FA3L4 worth?
The government has obligated $11,820 on SPE2DR26FA3L4.
Is contract SPE2DR26FA3L4 an order under another contract?
Yes. SPE2DR26FA3L4 is a delivery order under SPE2DR25D2014, an indefinite delivery contract.
Was contract SPE2DR26FA3L4 competed?
The extent of competition for SPE2DR26FA3L4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award